PAPZIMEOS revenue growth trajectory and positive cash flow achievement are the key metrics to track. Monitor the pace of patient hub enrollment and conversion to treated patients, as well as the EMA MAA decision for European expansion.
Drug in focus
PGEN drug pipeline →PAPZIMEOS
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched (August 2025).
- Next catalyst
- None dated
What to watchWatch for the pace of PAPZIMEOS revenue growth in upcoming quarterly reports, particularly whether the drug can maintain its 37% sequential growth trajectory against the new competition from Inovio's VOCERYQ, which was approved on October 30, 2026. Also monitor for a potential EMA marketing authorization application decision for European expansion, which could open a new market.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $4.22entry
- T+1 · 11d ago +5.92%α +5.61% · $4.47
- T+5 · 5d ago +10.43%α +7.14% · $4.66
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Precigen reported Q3 2026 revenue of $74.1M (vs. $71.6M consensus) and GAAP diluted EPS of $0.08 (in line with consensus). PAPZIMEOS net revenue grew 37% sequentially to $72.9M, and the company achieved positive operating cash flow of $11.9M, a full quarter ahead of guidance. Net income was $35.8M, a major swing from a $146.3M net loss in Q3 2025.
Key Financial Metrics
Key Facts
- PAPZIMEOS net revenue of $72.9M in Q3 2026, up 37% sequentially from $21.6M in Q1 2026
- Total revenue of $74.1M vs. $71.6M consensus
- GAAP diluted EPS of $0.08, in line with $0.08 consensus
- Net income of $35.8M vs. net loss of $146.3M in Q3 2025
- Positive operating cash flow of $11.9M, achieved a full quarter ahead of guidance
- Cash, cash equivalents and investments of $51.0M as of September 30, 2026
- FDA Platform Technology Designation granted to AdenoVerse platform in September 2026
- Launch-to-date PAPZIMEOS net product revenue of $151M
Financial Impact
PAPZIMEOS revenue of $72.9M, total revenue $74.1M, net income $35.8M, operating cash flow $11.9M
Risk Factors
- Dependence on single product PAPZIMEOS for revenue
- PAPZIMEOS revenue concentration with trade receivables of $96.5M (collection risk)
- Long-term debt of $94.3M remains on balance sheet
- Pipeline stage candidates (PRGN-2009) are still in Phase 2 with no near-term revenue
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-016970 |
| Document: dp256359_8k.htm | 0000950103-26-016970 |
| Document: 0000950103-26-016970-index-headers.html | 0000950103-26-016970 |
| Document: 0000950103-26-016970-index.html | 0000950103-26-016970 |
| Document: 0000950103-26-016970.txt | 0000950103-26-016970 |
| 8-K Data (Synthetic) | 0000950103-26-016970 |
Track record
13 reports on PGEN
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +52.17% at T+60 after the May 13, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
- Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
- Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
- Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
- Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
- Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers